Document is current
Any future updates will be listed below
-
Authors
De Block, Christophe https://orcid.org/0000-0002-0679-3203
Peleshok, Jennifer
Wilding, John P. H. https://orcid.org/0000-0003-2839-8404
Kwan, Anita Y. M. https://orcid.org/0000-0003-4696-5388
Rasouli, Neda https://orcid.org/0000-0003-1269-3580
Maldonado, Juan M. https://orcid.org/0000-0002-1370-327X
Wysham, Carol
Liu, Minzhi
Aleppo, Grazia
Benneyworth, Brian D. https://orcid.org/0000-0002-4692-5303
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03954834 at ClinicalTrials.govnct03987919 at ClinicalTrials.govDocuments that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
nct03882970 at ClinicalTrials.govDocuments that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
https://doi.org/10.1007/s13300-023-01398-1
nct03730662 at ClinicalTrials.govDocuments that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
https://doi.org/10.1007/s13300-023-01398-1
nct04039503 at ClinicalTrials.govDocuments that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
Documents that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (N/App)
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 8 October 2024
First Online: 12 November 2024
Declarations
:
: Christophe De Block has received consulting fees and honoraria for speaking from: Abbott, A. Menarini Diagnostics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Medtronic, Novo Nordisk, and Roche. John P. H. Wilding is a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Napp, Novo Nordisk, Mundipharma, Rhythm Pharmaceuticals, Sanofi, and Saniona, a grant holder (University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk, and has received personal honoraria / lecture fees from AstraZeneca, Boehringer Ingelheim and Napp. Neda Rasouli receives research funding from Eli Lilly and Company and Novo Nordisk, and a consultant for Eli Lilly and Company, Novo Nordisk and Sanofi. Carol Wysham has received support from Novo Nordisk, Eli Lilly and Company, Biomea, Abbott, CeQur, Fractyl Health, and Abvance. Grazia Aleppo has received research support to her employer from Fractyl Health, Insulet, MannKind, Tandem Diabetes, and Welldoc; Grazia Aleppo has received consulting fees from Medscape, Dexcom, and Insulet. Jennifer Peleshok, Anita Y. M. Kwan, Juan M. Maldonado, and Brian D. Benneyworth are full-time employees of Eli Lilly and Company and are minority holders of company stock. Minzhi Liu reports no commercial or financial relationships that could be construed as a potential conflict of interest.
: The SURPASS trials were conducted in accordance with consensus ethical principles, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations and were approved by the relevant ethics committee/review board at each site. All participants in all primary trials provided written informed consent. Each trial was registered with ClinicalTrials.gov: identifiers NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503.
